Poly Medicure Limited (NSE:POLYMED)
India · Delayed Price · Currency is INR 1,868.00
+95.60 (5.39%)
Aug 11, 2026, 3:29 PM IST
Poly Medicure Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 19,891 | 18,753 | 16,698 | 13,758 | 11,152 | 9,231 | |
Revenue Growth | 17.82% | 12.30% | 21.37% | 23.36% | 20.82% | 17.37% |
Cost of Revenue | 6,093 | 5,968 | 5,588 | 4,867 | 4,090 | 3,506 |
Gross Profit | 13,798 | 12,784 | 11,110 | 8,891 | 7,062 | 5,724 |
Selling, General & Admin | 4,548 | 4,023 | 3,106 | 2,516 | 2,076 | 1,671 |
Research & Development | 304.83 | 298.76 | 245.71 | 194.42 | 178.03 | 187.71 |
Other Operating Expenses | 4,417 | 4,040 | 3,219 | 2,584 | 2,109 | 1,730 |
Operating Expenses | 10,553 | 9,516 | 7,394 | 5,928 | 4,934 | 4,128 |
Operating Income | 3,245 | 3,268 | 3,716 | 2,963 | 2,128 | 1,596 |
Interest Expense | -218.42 | -182.91 | -116.93 | -109.34 | -62.27 | -38.28 |
Interest & Investment Income | - | - | 117.83 | 118.36 | 153.29 | 94.75 |
Earnings From Equity Investments | 59.13 | 56.84 | 51.8 | 25.27 | 19.27 | 24.47 |
Currency Exchange Gain (Loss) | - | - | 213.27 | 152.83 | 113.82 | 118.84 |
Other Non Operating Income (Expenses) | 1,201 | 1,201 | 83.7 | 62.4 | 62.26 | 55.11 |
EBT Excluding Unusual Items | 4,286 | 4,343 | 4,066 | 3,212 | 2,414 | 1,851 |
Gain (Loss) on Sale of Investments | - | - | 439.96 | 209.49 | -40.07 | 96 |
Gain (Loss) on Sale of Assets | - | - | 1.2 | 6.23 | 1 | 5.31 |
Other Unusual Items | -68.04 | -68.04 | 18.04 | 14.53 | - | - |
Pretax Income | 4,218 | 4,275 | 4,525 | 3,443 | 2,375 | 1,952 |
Income Tax Expense | 1,089 | 1,067 | 1,140 | 860.09 | 582.09 | 487.39 |
Earnings From Continuing Operations | 3,129 | 3,207 | 3,386 | 2,583 | 1,793 | 1,465 |
Minority Interest in Earnings | 21.61 | 14.1 | - | - | - | - |
Net Income | 3,151 | 3,221 | 3,386 | 2,583 | 1,793 | 1,465 |
Net Income to Common | 3,151 | 3,221 | 3,386 | 2,583 | 1,793 | 1,465 |
Net Income Growth | -11.89% | -4.85% | 31.09% | 44.05% | 22.37% | 7.83% |
Shares Outstanding (Basic) | 101 | 101 | 99 | 96 | 96 | 96 |
Shares Outstanding (Diluted) | 101 | 101 | 99 | 96 | 96 | 96 |
Shares Change | 0.82% | 2.23% | 3.36% | - | 0.06% | 7.64% |
EPS (Basic) | 31.09 | 31.79 | 34.13 | 26.92 | 18.69 | 15.28 |
EPS (Diluted) | 31.06 | 31.75 | 34.11 | 26.90 | 18.67 | 15.27 |
EPS Growth | -12.60% | -6.92% | 26.80% | 44.08% | 22.27% | 0.20% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -620.17 | -906.06 | -109.34 | -482.23 | -321.06 |
Free Cash Flow Per Share | - | -6.11 | -9.13 | -1.14 | -5.02 | -3.35 |
Dividend Per Share | - | 3.500 | 3.500 | 3.000 | 3.000 | 2.500 |
Dividend Growth | - | 0% | 16.67% | 0% | 20.00% | 0% |
Gross Margin | 69.37% | 68.17% | 66.53% | 64.63% | 63.32% | 62.02% |
Operating Margin | 16.31% | 17.43% | 22.25% | 21.54% | 19.08% | 17.29% |
Profit Margin | 15.84% | 17.18% | 20.28% | 18.77% | 16.08% | 15.87% |
Free Cash Flow Margin | - | -3.31% | -5.43% | -0.80% | -4.32% | -3.48% |
EBITDA | 4,488 | 4,423 | 4,521 | 3,577 | 2,677 | 2,118 |
EBITDA Margin | 22.56% | 23.59% | 27.08% | 26.00% | 24.01% | 22.94% |
D&A For EBITDA | 1,243 | 1,155 | 805.07 | 614.02 | 549.8 | 521.67 |
EBIT | 3,245 | 3,268 | 3,716 | 2,963 | 2,128 | 1,596 |
EBIT Margin | 16.31% | 17.43% | 22.25% | 21.54% | 19.08% | 17.29% |
Effective Tax Rate | 25.82% | 24.97% | 25.18% | 24.98% | 24.51% | 24.96% |
Revenue as Reported | 21,092 | 19,953 | 17,590 | 14,345 | 11,514 | 9,610 |
Advertising Expenses | - | - | 60.5 | 33.91 | 28.51 | 12.89 |